MAPK8 and Insulin resistance: Recently, we reported that a dipeptidyl peptidase 4 inhibitor improves hepatic steatosis as well as insulin resistance through AMP-activated protein kinase (AMPK)- and JNK-dependent inhibition of LECT2 expression [11].